SG11202007381YA - Novel small molecule drug conjugates of gemcitabine derivatives - Google Patents

Novel small molecule drug conjugates of gemcitabine derivatives

Info

Publication number
SG11202007381YA
SG11202007381YA SG11202007381YA SG11202007381YA SG11202007381YA SG 11202007381Y A SG11202007381Y A SG 11202007381YA SG 11202007381Y A SG11202007381Y A SG 11202007381YA SG 11202007381Y A SG11202007381Y A SG 11202007381YA SG 11202007381Y A SG11202007381Y A SG 11202007381YA
Authority
SG
Singapore
Prior art keywords
small molecule
drug conjugates
molecule drug
novel small
gemcitabine derivatives
Prior art date
Application number
SG11202007381YA
Other languages
English (en)
Inventor
Steven Albert Everett
Craig Alan Coburn
Original Assignee
Maverix Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverix Oncology Inc filed Critical Maverix Oncology Inc
Publication of SG11202007381YA publication Critical patent/SG11202007381YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/24—Post-translational modifications [PTMs] in chemical analysis of biological material hydroxylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SG11202007381YA 2018-02-02 2019-02-04 Novel small molecule drug conjugates of gemcitabine derivatives SG11202007381YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862625779P 2018-02-02 2018-02-02
PCT/US2019/016477 WO2019152911A1 (fr) 2018-02-02 2019-02-04 Nouveaux conjugués de médicaments à petites molécules de dérivés de gemcitabine

Publications (1)

Publication Number Publication Date
SG11202007381YA true SG11202007381YA (en) 2020-08-28

Family

ID=65494546

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007381YA SG11202007381YA (en) 2018-02-02 2019-02-04 Novel small molecule drug conjugates of gemcitabine derivatives

Country Status (13)

Country Link
US (1) US20210380626A1 (fr)
EP (1) EP3746133A1 (fr)
JP (2) JP2021512951A (fr)
KR (1) KR20200118828A (fr)
CN (1) CN112135635A (fr)
AU (1) AU2019216514A1 (fr)
BR (1) BR112020015747A2 (fr)
CA (1) CA3090272A1 (fr)
EA (1) EA202091857A1 (fr)
IL (1) IL276442A (fr)
PH (1) PH12020551178A1 (fr)
SG (1) SG11202007381YA (fr)
WO (1) WO2019152911A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019216531A1 (en) * 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
CN114349816B (zh) * 2021-11-30 2024-08-30 潍坊博创国际生物医药研究院 一种基于氨肽酶n/cd13的小分子偶联分子及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243520T1 (de) 1998-02-12 2003-07-15 Univ Montfort Durch hydroxylierung aktivierte wirkstofffreigabe
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2015081867A1 (fr) * 2013-12-04 2015-06-11 杭州民生药物研究院有限公司 Dérivé de gemcitabine, composition contenant le dérivé et utilisation pharmaceutique du dérivé
WO2015134334A1 (fr) * 2014-03-03 2015-09-11 Suo Zucai Analogues de gemcitabine
CN105001291B (zh) * 2014-04-15 2018-12-04 上海知萌生物医药科技有限公司 吉西他滨化学传递前药及其制备方法和应用
US20180044368A1 (en) * 2015-02-25 2018-02-15 Ligand Pharmaceuticals, Inc. Gemcitabine derivatives

Also Published As

Publication number Publication date
EP3746133A1 (fr) 2020-12-09
AU2019216514A1 (en) 2020-09-24
IL276442A (en) 2020-09-30
JP2021512951A (ja) 2021-05-20
KR20200118828A (ko) 2020-10-16
CA3090272A1 (fr) 2019-08-08
PH12020551178A1 (en) 2021-06-07
EA202091857A1 (ru) 2020-12-04
WO2019152911A1 (fr) 2019-08-08
CN112135635A (zh) 2020-12-25
JP2024073414A (ja) 2024-05-29
BR112020015747A2 (pt) 2020-12-08
US20210380626A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
DK3652215T3 (da) Forbedret polypeptidmolekyle med dobbelt specificitet
DK3592393T3 (da) Frigørbare konjugater
EP3471771A4 (fr) Conjugués anticorps-médicaments ayant des dérivés d'amatoxine en tant que médicament
MX2017008215A (es) Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina.
IL291308A (en) Drug-antibody conjugates with enzymatically cleavable groups
DK3935068T3 (da) Abirateron-prodrugs
DK3870234T3 (da) Antistoflægemiddelkonjugater omfattende ecteinascidinderivater
IL271859A (en) Continuous production of drug molecule conjugates for guidance
IL273528A (en) Long-term conjugates of GLP-2 derivatives
AU2018297348A1 (en) Compositions for parenteral administration of therapeutic agents
MA49127A (fr) Dérivés d'indole n-substitués
DK3790874T3 (da) Anthelmintiske kinolinderivater
EP3479828A4 (fr) Composition médicamenteuse pour administration parentérale
MA41542A (fr) Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase
EP3600341A4 (fr) Dérivés de gemcitabine pour la thérapie du cancer
IL270979A (en) Pharmaceutical formulations for small molecules that are resistant to sedimentation
DK3583943T3 (da) Farmaceutisk sammensætning
DK3666787T3 (da) Antistoflægemiddelkonjugater som inkluderer hemiasterlinderivat
DK3652176T3 (da) Substituerede xanthinderivater
TR201901977T4 (tr) Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.
IL276442A (en) New small molecule drug conjugates of gemcitabine history
DK4056557T3 (da) Benzazepinderivater nyttige som medikamenter
DK3672631T3 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
EP3701937A4 (fr) Composition pharmaceutique stable contenant un dérivé de médicament anti-inflammatoire non stéroïdien
IL276436A (en) Gemcitabine monophosphate small molecule drug conjugates